Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly ...

Prurigo nodularis (PN) is challenging to treat, but new treatments show promise. Let’s look at symptoms and lots of ways to manage PN.

Prurigo nodularis is an inflammatory skin condition that causes the development of intensely itchy skin and bumps or lumps (nodules) on the legs, arms, upper back, or abdomen. This article ...

The global prurigo nodularis market is surging due to rising prevalence, increased awareness, and treatment innovations. Key drivers include advanced biologic therapies like dupilumab, addressing ...

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis ...

The encouraging long-term efficacy and safety associated with nemolizumab (IL-31 inhibitor) in prurigo nodularis was supported by a second set of data showing long-term benefit in atopic dermatitis.

Predictors of perceived stress, perceived stigmatization, and body dysmorphia in patients with chronic prurigo/prurigo nodularis: Results from an observational cross-sectional multicenter European ...

The first and only treatment for the disabling skin condition prurigo nodularis has been approved by the Food and Drug Administration in a development a D.C. dermatologist calls “huge.” ...

The FDA approved Nemluvio in the form of a prefilled pen for subcutaneous injection for the treatment of prurigo nodularis in adults, Galderma announced in a press release.“The U.S. FDA’s ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...

Galderma’s nemolizumab has been shown to improve the core signs and symptoms of prurigo nodularis, according to phase 3 results published in JAMA Dermatology. The 24-week OLYMPIA 1 trial evaluated the ...

“Dupixent has the potential to transform the standard-of-care for prurigo nodularis patients by alleviating the key hallmarks of the disease, such as reducing itch and achieving clearer skin.” The FDA ...